Abstract:Objective: To identify novel polymorphisms in the solute carrier SLC22A16 gene and determine their influence on the pharmacokinetics of doxorubicin and doxorubicinol in Asian breast cancer patients. Methods: SLC22A16 coding regions were screened in a total of 400 healthy subjects belonging to three distinct Asian ethnic groups (Chinese [n = 100], Malays [n = 100] and Indians [n = 100]) and in the Caucasian population (n = 100). Pharmacokinetic parameters of doxorubicin and doxorubicinol were estimated in Asian breast cancer patients undergoing adjuvant chemotherapy to investigate genotype–phenotype correlations. Results: Four novel polymorphisms (c.146A>G [exon 2], c.312T>C, c.755T>C [exon 4] and c.1226T>C [exon 5]) were identified. The genotypic frequency of the homozygous c.146GG polymorphism was approximately twofold higher in the healthy Chinese (13%) & Malay (18%) populations compared with the Indian (7%) and Caucasian (9%) populations. The genotypic frequency of the c.1226T>C polymorphism was observed to be significantly higher among the Caucasian (11%) and Indian (8%) study subjects compared with the Chinese (1%) and Malay (1%) ethnic groups (p < 0.005 in each case). Breast cancer patients harboring the 146GG genotype showed a trend towards higher exposure levels to doxorubicin (AUC0–∞/dose/body surface area [BSA] [hm-5]: 21.6; range: 18.8–27.7) compared with patients with either the reference genotype (AUC0–∞/dose/BSA[hm-5]: 17.4; range: 8.2–26.3, p = 0.066) or heterozygotes (AUC0–∞/dose/BSA[hm-5]: 15.4; range: 6.2–38.0, p = 0.055). The exposure levels of doxorubicinol were also higher in patients harboring the variant 146GG genotype (AUC0–∞/dose/BSA[hm-5]: 13.3; range: 8.8–21.7) when compared with patients harboring the reference genotype (AUC0–∞/dose/BSA[hm-5]): 9.8; range: 6.1–24.3, p = 0.137) or heterozygotes (AUC0–∞/dose/BSA[hm-5]: 8.98; range: 3.7–20.6, p = 0.047). Conclusion: Among the four novel SLC22A16 polymorphisms identified, the c.146A>G and c.1226T>C polymorphisms exhibited interethnic variations in allele and genotype frequencies. This exploratory study suggests that the c.146A>G variation could contribute to the variations in the pharmacokinetics of doxorubicin and doxorubicinol in Asian cancer patients. Further in vitro studies are required to determine the functional impact of these novel polymorphisms on doxorubicin pharmacokinetics in cancer patients.

Hepatic Expression of CYP3A4 and CYP3A5 Genes in Asians and Implications for Pharmacokinetic Variations During Chemotherapy

Identification and Functional Assessment of EightCYP3A4Allelic Variants39–46Detected in the Chinese Han Population

Novel SLC22A16 Polymorphisms and Influence on Doxorubicin Pharmacokinetics in Asian Breast Cancer Patients

Pharmacogenetics of SLCO1B1: Haplotypes, Htsnps and Hepatic Expression in Three Distinct Asian Populations

Differences in Genotype and Allele Frequency Distributions of Polymorphic Drug Metabolizing Enzymes CYP2C19 and CYP2D6 in Mainland Chinese Mongolian, Hui and Han Populations

Influence Of Abcb1 And Abcg2 Polymorphisms On Doxorubicin Disposition In Asian Breast Cancer Patients

Identification and Functional Assessment of Eight CYP3A4 Allelic Variants 39-46 Detected in the Chinese Han Population

Differences in cytochrome P4502C19 (CYP2C19) expression in adjacent normal and tumor tissues in chinese cancer patients

Genetic Polymorphisms And In Silico Mutagenesis Analyses Of Cyp2c9, Cyp2d6, And Cypor Genes In The Pakistani Population

Association of CYP2C19*3 Gene Polymorphism with Breast Cancer in Chinese Women.

[Polymorphisms of Drug-Metabolizing Enzymes Genes in a Han Chinese Population].

Carbonyl Reductase 1 Polymorphisms: Influence of Diplotype Structures on Doxorubicin Disposition in Asian Breast Cancer Patients

Genetic Polymorphisms of Cyclophophamide-Metabolizing Enzymes and Their Association with Chemotherapy Responses in Breast Cancer

Frequencies of Poor Metabolizers of Cytochrome P450 2C19 in Esophagus Cancer, Stomach Cancer, Lung Cancer and Bladder Cancer in Chinese Population

Thiopurine Methyltransferase Gene Polymorphisms in Chinese Patients with Inflammatory Bowel Disease

Pharmacogenetics of SLCO1B1 Gene and the Impact of 1b and 15 Haplotypes on Irinotecan Disposition in Asian Cancer Patients

Pharmacokinetics of CYP2C9, CYP2C19, and CYP2D6 Substrates in Healthy Chinese and European Subjects.

P5-19-07: the Effects of ABCC2 and SLCO1B3 Single Nucleotide Polymorphisms on Docetaxel-Induced Leukopenia in Breast Cancer Patients.

Differences in cytochrome P450 2C19 (CYP2C19) expression in adjacent normal and tumor tissues in Chinese cancer patients.

Systematic Screening for Polymorphisms in the CYP3A4 Gene in the Chinese Population.

Characteristic CYP2A6 genetic polymorphisms detected by TA cloning-based sequencing in Chinese digestive system cancer patients with S-1 based chemotherapy.